Entera Bio Reports Increased Operating Losses and No Revenue in Q2 2026

Entera Bio Ltd. reported its financial results for the second quarter of 2026, revealing a significant increase in operating losses compared to the same period in 2025. The company recorded a net loss of $7.3 million for the three months ended June 30, 2026, up from a loss of $2.7 million in the prior year, marking a 175% increase. For the six months ended June 30, 2026, the net loss was $10.8 million, compared to $5.2 million for the same period in 2025. The increase in losses is attributed to heightened research and development expenses, which rose to $3.2 million for the quarter, a 111% increase from $1.5 million in the previous year.

The company did not generate any revenue during the second quarter of 2026, a decline from $42,000 reported in the same quarter of 2025. This drop is linked to the completion of obligations under a prior research services agreement. Total operating expenses for the second quarter were $4.6 million, up from $2.7 million in the same quarter of 2025, driven primarily by increased research and development costs associated with the advancement of its product candidates, particularly EB613, an oral treatment for osteoporosis.

In terms of strategic developments, Entera Bio completed a private placement on July 28, 2026, raising approximately $275 million before expenses. The proceeds from this financing are earmarked for supporting the Phase 3 registrational study of EB613 and for general corporate purposes. The company also amended its collaboration agreement with OPKO Biologics to expand the scope of their partnership, which includes the development of EB612, an oral treatment for hypoparathyroidism.

Operationally, Entera Bio's employee count stood at 22 as of June 30, 2026, all based in Israel. The company has focused on advancing its N-Tab® platform, which is designed to facilitate the oral delivery of peptides. Despite the ongoing regional conflict in Israel, the company reported that its operations have remained largely unaffected, and it does not anticipate any delays in its clinical programs as a result of the conflict.

Looking ahead, Entera Bio expects to continue incurring significant operating losses as it advances its clinical development programs. The company believes that its existing cash resources, bolstered by the recent private placement, will be sufficient to fund its operations into 2030. However, it acknowledges the inherent uncertainties in drug development and the potential need for additional capital in the future to support its strategic initiatives.